Invest in the best stock opportunities right now and every time.
Start Systematic Stock Investing …in less than a minute.
Zydus Cadila has completed Phase 3 Clinical Trial in India of Saroglitazar Magnesium for treating Type 2 Diabetes. The trial was a multi-centric, randomized, double blind study to evaluate the safety and efficacy of 2mg and 4mg of Saroglitazar compared to Pioglitazone 45mg in patients with Type 2 Diabetes Mellitus. The Phase 3 trial enrolled 1140 subjects and studied the patients over a period of 56 weeks.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 826.70 |
Cipla | 950.10 |
Dr. Reddy's Lab | 4384.35 |
Aurobindo Pharma | 522.55 |
Lupin | 628.55 |
View more.. |